Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$0.87 USD

0.87
490,626

+0.01 (1.72%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.90 +0.03 (2.87%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

by Zacks Equity Research

Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.

Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.

Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?

by Zacks Equity Research

Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect increasing patient days and admissions.

Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?

by Zacks Equity Research

Universal Health's (UHS) fourth-quarter results are likely to reflect improved performances from the Acute Care Hospital Services and Behavioral Health Care Services businesses.

Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.

Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?

by Zacks Equity Research

Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.

Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.

Kinjel Shah headshot

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

by Kinjel Shah

Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

Are Medical Stocks Lagging Amarin (AMRN) This Year?

by Zacks Equity Research

Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

by Zacks Equity Research

Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million. Stock gains.

Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

What Makes Amarin (AMRN) a New Buy Stock

by Zacks Equity Research

Amarin (AMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.

Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Amarin (AMRN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss

by Zacks Equity Research

Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.

Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall

by Zacks Equity Research

Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Ekta Bagri headshot

Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

by Ekta Bagri

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.

Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.

Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.

GSK Gears Up to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.

Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.